Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSQPCT)

Drug Name
ALXN1850 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hypophosphatasia 5C64.3 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMSQPCT

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Alkaline phosphatase tissue-nonspecific (ALPL) TTMR5UV PPBT_HUMAN Replacement [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Alkaline phosphatase tissue-nonspecific (ALPL) DTT ALPL 6.35 4.07 5.7 3.609
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hypophosphatasia
ICD Disease Classification 5C64.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Alkaline phosphatase tissue-nonspecific (ALPL) DTT ALPL 4.67E-13 -0.15 -0.79
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04980248) A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Alexion